Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the best stocks under $5 with highest upside potential. On October 28, Needham lifted its price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $8 from $6 while keeping a Buy rating on the stock. The firm told investors that it is more optimistic about the company’s outlook after its R&D Investor Event that exhibited its broad pipeline.

Similarly, Guggenheim upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) to Buy from Neutral on October 27, setting a $14 price target on the shares. The firm told investors that it released the rating update after the “compelling” preclinical obesity data reported by Neumora Therapeutics, Inc. (NASDAQ:NMRA). Guggenheim added that it believes the company’s NLRP3i program in obesity and related disorders to be “a clear driver to value creation.”

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biotechnology company that integrates neuroscience and data science to offer a precision medicine approach for brain diseases. Its focus is on advancing medicines for therapeutically relevant targets implicated in CNS diseases.

While we acknowledge the potential of NMRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.